FDA approves Aclidinium (Tudorza Pressair), a b.i.d. "me-too" to Spiriva for COPD
www.pulmccm.org
July 29, 2012 Last week, the FDA approved aclidinium bromide (Tudorza Pressair) as a daily inhaler treatment for chronic obstructive pulmonary disease (COPD), the agency announced in a press release. Aclidinium is a long-acting muscarinic antagonist (or "anticholinergic") bronchodilator that will compete with tiotropium (Spiriva), which was launched in 2004 and until now was the only available anticholinergic bronchodilator inhaler therapy for COPD.
FDA approves Aclidinium (Tudorza Pressair), a b.i.d. "me-too" to Spiriva for COPD
FDA approves Aclidinium (Tudorza Pressair), a…
FDA approves Aclidinium (Tudorza Pressair), a b.i.d. "me-too" to Spiriva for COPD
July 29, 2012 Last week, the FDA approved aclidinium bromide (Tudorza Pressair) as a daily inhaler treatment for chronic obstructive pulmonary disease (COPD), the agency announced in a press release. Aclidinium is a long-acting muscarinic antagonist (or "anticholinergic") bronchodilator that will compete with tiotropium (Spiriva), which was launched in 2004 and until now was the only available anticholinergic bronchodilator inhaler therapy for COPD.
Comments on this post are for paid subscribers